Public procurement notice: Contract Award Notice
Published: 2022-01-31
Buyer: SYKEHUSINNKJØP HF
Country: NO
Contract type: Supplies
Procedure: Negotiated without a prior call for competition
CPV classification: 33000000 | 33696500 | 38000000
Estimated value: 83400000 NOK
Award criteria: The most economic tender

Technical requirements: Oslo universitetssykehus HF [Oslo University Hospital Trust] has entered into a framework agreement with Montebello Diagnostics AS for the delivery of Kits for Panther Fusion for nucleic acid detection of the respiratory microbes Adenovirus, Bordetella pertussis, Human metapneumovirus, Influenza virus type A, Influenza virus type B, Parainfluenza virus, type 1, 2, 3 and 4, Respiratory syncytial virus (RSV) and Rhinovirus, as well as other consumables including ‘Open access’-kit.
Use of ‘open access’-kits for detection of other respiratory microbes, as well as up to 10% general increase due to increased need for the analyses.
Comments concerning the value stated in point II.1.7: The annual value of the procurement and contract including options is approx. NOK 8.3 million. The contract duration is for the anticipated life-time of the instruments, and that is considered to be 10 years.
When IVDR enters into force the Unit for Molecular Diagnostics and Virology at Ullevål  (MoV) must replace multiple/many of their current in-house-respiratory analyses with commercial CE-labelled PCR kits in order to satisfy the requirements in accordance with the new regulation. There are no investment funds available to purchase new equipment. The current analyses must therefore be replaced by analyses that can be performed on equipment MoV already has. This applies to both the extraction and detection stages. Respiratory analyses are analyses where there is a need for a quick test response, and this means that MoV must have equipment-backup available in their own laboratory. The respiratory analyses that are currently detected through the use of in-house methods are Adenovirus, Bordetella pertussis, Chlamydia pneumoniae, Enterovirus D68, Human metapneumovirus, Influenza virus type A, Influenza virus type B, Mycoplasma pneumoniae, Parainfluenza virus, type 1, 2, 3 and 4, Respiratory syncytial virus (RSV) and Rhinovirus.  In 2019 the combined number of analyses for these was approx.  89,000.  It is anticipated that detection of SARS-CoV-2 will be assessed in the same way as the other respiratory analyses after the end of the pandemic and therefore this procurement must also include kits for SARS-CoV-2, possibly with the analysis included in the same kit as influenza.
Hologic has sole-rights to the equipment Panther Fusion and to the assay kits for this equipment, and Hologic distributes products in Norway via Montebello Diagnostics. For respiratory analyses there is a need for quick answers, and the requisitioners need clarification on these for further treatment and isolation of their patients. Our current response time of one working day as long as the sample is received on the same working day by 10:00. Therefore, there must be back-up for the equipment used for the analyses, so that the analyses can be carried out as planned or in the event of unforeseen downtime on an instrument.  MoV owns two Panther Fusion instruments, but only one Cobas 6800.  During the pandemic they borrow an extra Cobas 6800, but it is installed in another department location.  There is neither funding to purchase new equipment or space to install more equipment in MoV’s premises. It is therefore not possible to meet the requirement for back-up in any other way than by performing the respiratory passage analyses after transition to commercial kits performed on Panther Fusion.
The delivery of kits for Panther Fusion for nucleic acid detection of respiratory microbes for Oslo University Hospital Trust.


Winner: Montebello Diagnostics AS
Award value: 83400000
Number of bids: 1